Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

By A. Rush, Madhukar H. Trivedi, S. Wisniewski, J. Stewart, A. Nierenberg, M. Thase, Louise Ritz, M. Biggs, D. Warden, J. Luther and 3 more. New England Journal of Medicine, 2006

1,014 citations recorded by the source corpus.

Subfields: Biological Psychiatry, Experimental and Cognitive Psychology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/508710f508a7ac80681978ae50635812332a6731

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

W. Bernet
O. Bukstein
H. Walter
R. S. Benson
Allan K. Chrisman
Tiffany R. Farchione
L. Greenhill
J. Hamilton

Citations in the corpus

Depression and cardiovascular disease: a clinical review. (2014, background): “In non-cardiac patients, after initially trying the SSRI citalopram, switching to another anti-depressant can result in additional benefits.(88) Because it more resembles a tricyclic antidepressant when”
Major depression. (2014, background): “After failure to respond to citalopram, 25% of subjects experienced remission with switching medications to another SSRI or to a different class of medications (venlafaxine, bupropion).(125) Alternatively, 30% of subjects experienced remission with augmentation of the SSRI with bupropion or buspiron”
Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. (2007, background): “In a landmark study of treatment-resistant depressed adults, after unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant (Rush et al., 2006 [rct], Trivedi et al., 2006 [rct]).”
Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. (2017, neutral): “Examples include (1) treatment of primary psychiatric conditions other than MDD without psychotic features,76,77 (2) administering more than 3,000 pulses per session,78 (3) stimulation of the right prefrontal cortex,10,72 and (4) use of devices with FDA approval for delivering peripheral nerve stimu”
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report (2006, neutral): “137 [100 37 19]).”